TY  - JOUR

T1  - Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer

JO  - Anti-Cancer Drugs

PY  - 1999/01/01

AU  - Possinger K

AU  - Kaufmann M

AU  - Coleman R

AU  - Stuart NSA

AU  - Helsing M

AU  - Ohnmacht U

AU  - Arning M

ED  - 

DO  - DOI: 10.1097/00001813-199902000-00003

PB  - Ovid Technologies (Wolters Kluwer Health)

VL  - 10

IS  - 2

SP  - 155

EP  - 162

Y2  - 2025/10/10

ER  -